Tri-Allelic Human Leukocyte Antigen (HLA) Protection Against Dementia

Lisa M. James1,2,3, Apostolos P. Georgopoulos1,2,3,4,*

1 Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, USA
2 Department of Neuroscience, University of Minnesota Medical School, Minneapolis, USA
3 Department of Psychiatry, University of Minnesota Medical School, Minneapolis, USA
4 Department of Neurology, University of Minnesota Medical School, Minneapolis, USA

ABSTRACT

Human Leukocyte Antigen (HLA) Class II DRB1*13:02 has recently been found to protect against dementia in Continental Western Europe. Here we extend those findings by evaluating the association between the population frequency of two additional Class II HLA alleles – DRB1*01:01 and DRB1*15:01 – alone and in combination with DRB1*13:02, on dementia prevalence in Continental Western Europe. Results indicated that the prevalence of dementia in 14 Continental Western European (CWE) countries significantly decreased exponentially with increasing frequency of any of the three alleles alone and in combination (P's < 0.001). When combined, the population frequency of the three alleles accounted for 67% of the variance in dementia prevalence. The combined frequency of DRB1*01:01, DRB1*13:02, and DRB1*15:01 was also significantly associated with dementia prevalence in those aged 65 years and older (P = 0.004) and with a change in dementia prevalence between 1990 and 2016 (P = 0.006). These findings, which document the protective effects of three common Class II HLA alleles on dementia prevalence in CWE, are discussed in terms of the role of HLA class II genes in pathogen elimination. More specifically, we hypothesize that dementia prevalence is higher for countries in which the population frequency of these protective alleles is low, prohibiting the successful elimination of pathogens that may play a causal role in dementia.

Introduction

Recent evidence points to immunogenetic protection against age-related brain changes1,2 and dementia3 conferred by human leukocyte antigen (HLA) DRB1*13:02, a class II allele. HLA genes, which are located in the Major Histocompatibility Complex (MHC) of chromosome 6, code for cell-surface glycoproteins that facilitate the elimination of foreign antigens and, therefore, play a critical role in host protection. Class II HLA alleles (DRB, DQB, DPB) present exogenous antigenic peptides, such as those derived from viruses and bacteria, to CD4 receptors to promote antibody production. Antibody production and subsequent elimination of foreign antigens, however, are predicated on good binding affinity between HLA and epitopes of foreign antigens coupled with the resulting immunogenicity. Sufficient affinity/immunogenicity results in immunological memory and host protection in the event of re-exposure; however, poor affinity/immunogenicity may lead to antigen persistence and, consequently, neuronal damage4,5 and possibly dementia4,6. Indeed, several microbes have been associated with Alzheimer’s dementia7,8 and pathogens have been implicated in other forms of dementia as well9. We have hypothesized that the observed DRB1*13:02 protection against age-related brain changes and dementia is conferred by successful elimination of foreign antigens and have speculated that other HLA genes may similarly protect against pathogens that may be associated with dementia.
The HLA region is the most highly polymorphic in the human genome, having evolved to maximize species resistance to foreign antigens\textsuperscript{9,10}. Still, some alleles are considerably more common than others\textsuperscript{11,12}, presumably due to evolutionary advantage in conferring host protection. DRB1*13:02, for example, is one of the most common DRB alleles and has been shown to be highly protective against several conditions including various autoimmune disorders\textsuperscript{13,14}, Gulf War Illness\textsuperscript{15,16}, and infectious diseases\textsuperscript{17-19}. Furthermore, DRB1*13:02 has also been shown to protect against age-related brain atrophy\textsuperscript{1} and functional deterioration\textsuperscript{2} in cognitively healthy women, even after accounting for presence of apolipoprotein e4 (apoE4), a well-established genetic risk factor for dementia\textsuperscript{20}. This evidence of protective effects against age-related brain changes led us to hypothesize that DRB1*13:02 may protect against dementia. Indeed, in a recent genetic epidemiological study we evaluated the relationship between the population frequency of DRB1*13:02 and dementia prevalence in 14 CWE countries and found that dementia prevalence decreased exponentially with increasing frequency of DRB1*13:02, even after adjusting for the prevalence of apoE4.\textsuperscript{3} Remarkably, the population frequency of DRB1*13:02 accounted for 45% of the variance in dementia prevalence. In the 14 countries included in that study\textsuperscript{1}, the frequency of DRB1*13:02 ranged from 0.025-0.062, which equates to 5–13% carriers in the respective country population, suggesting that other factors, such as additional protective HLA alleles, may account for the remaining variance in dementia prevalence. Thus, in the present study, we evaluated the association between other common DRB1 alleles and dementia prevalence in the same 14 CWE countries.

### Methods

**CWE countries.** As in our previous study\textsuperscript{3}, we focused on the following 14 CWE countries: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Portugal, Norway, Spain, Sweden, and Switzerland.

**Prevalence of dementia.** As with our prior study\textsuperscript{3}, dementia prevalence was computed by dividing the number of people with dementia in 2016 in each country\textsuperscript{21} by the total population of the country in 2016\textsuperscript{22} and expressed as a percentage. In the present study, we also estimated dementia prevalence for those aged 65 and older by adjusting the total population prevalence obtained above by the percent of the population that is 65 or older\textsuperscript{22}. These data are shown in Table 1. We have previously shown that life expectancy for these countries are virtually identical\textsuperscript{3} (Table 1); therefore, life expectancy was not included in the current analyses.

**ApoE4 prevalence.** The apoE4 prevalence was obtained from published data\textsuperscript{23} and is shown in Table 2.

**HLA alleles.** In our previous study\textsuperscript{3} we identified DRB1*13:02 as having a protective role on dementia prevalence in the 14 CWE counties above. Here we sought to find out additional HLA DRB1 alleles, if any, with such a protective effect on dementia prevalence. For that purpose, we searched the publicly available database of immune gene frequencies (Allele Frequency Net Database, http://www.allelefrequencies.net) for DRB1 alleles that were genotyped at high (4 digit) resolution and were available for all the 14 CWE countries above. This search (on October 19, 2019) yielded 6 alleles (DRB1*01:01, DRB1*10:01, DRB1*11:01, DRB1*13:01, DRB1*13:02, DRB1*14:01) with complete data. We also found 5 alleles for which data were available for 13 countries (DRB1*03:01, DRB1*04:01,

### Table 1. Dementia prevalence and life expectancy for Countries in Continental Western Europe.

| Country | N Dementia\textsuperscript{a} | N total population\textsuperscript{b} | Fraction of population >65 y | N Population >65 y | Overall Dementia Prevalence | Estimated dementia prevalence in >65 y | Average life expectancy\textsuperscript{b} |
|---------|----------------|-----------------|----------------------------|-----------------|-----------------------------|---------------------------------|-------------------------------|
| Austria | 126914 | 8800000 | 0.18 | 1584000 | 1.442 | 8.012 | 81.5 |
| Belgium | 181350 | 11300000 | 0.18 | 2034000 | 1.605 | 8.916 | 81.5 |
| Denmark | 55336 | 5700000 | 0.19 | 1083000 | 0.971 | 5.109 | 80.5 |
| Finland | 83950 | 5500000 | 0.20 | 1100000 | 1.526 | 7.632 | 81.5 |
| France | 877760 | 64600000 | 0.18 | 11628000 | 1.359 | 7.549 | 82.0 |
| Germany | 1201668 | 82600000 | 0.21 | 17346000 | 1.455 | 6.928 | 80.5 |
| Greece | 192563 | 10800000 | 0.19 | 2052000 | 1.783 | 9.384 | 81.0 |
| Italy | 1370308 | 60600000 | 0.22 | 13332000 | 2.261 | 10.278 | 82.5 |
| Netherlands | 192425 | 17000000 | 0.18 | 3060000 | 1.132 | 6.288 | 81.5 |
| Norway | 67207 | 5200000 | 0.16 | 832000 | 1.292 | 8.078 | 82.0 |
| Portugal | 166660 | 10300000 | 0.20 | 2060000 | 1.618 | 8.909 | 80.0 |
| Spain | 830915 | 43300000 | 0.18 | 7794000 | 1.919 | 10.661 | 82.5 |
| Sweden | 142735 | 9900000 | 0.20 | 1980000 | 1.442 | 7.209 | 82.0 |
| Switzerland | 115476 | 8400000 | 0.18 | 1512000 | 1.375 | 7.637 | 83.0 |

\textsuperscript{a} Data obtained from ref\textsuperscript{21}.

\textsuperscript{b} Data obtained from ref\textsuperscript{22}.
DRB1*08:01, DRB1*12:01, DRB1*15:01); specifically, data for DRB1*03:01, DRB1*04:01, DRB1*08:01, and DRB1*12:01 were missing for Switzerland, and data for DRB1*15:01 were missing for Belgium. We could not find any data in the web for the Swiss-missing alleles but we did find DRB1*15:01 frequency for Belgium from a research publication\textsuperscript{24}. Thus we evaluated the relation to dementia prevalence for the following 7 alleles: DRB1*01:01, DRB1*10:01, DRB1*11:01, DRB1*13:01, DRB1*13:02, DRB1*14:01, and DRB1*15:01. Of those 7 alleles, only three (DRB1*01:01, DRB1*13:02 and DRB1*15:01) had a statistically significant protective effect on dementia prevalence (see below) and were analyzed further. The frequencies of these alleles for each country are given in Table 3.

### Table 2. ApoE4 prevalence per country in continental Western Europe.\textsuperscript{a}

| Country | Sample size | ApoE4 prevalence |
|---------|-------------|------------------|
| Austria | 683         | 0.105            |
| Belgium | 1660        | 0.128            |
| Denmark | 1620        | 0.127            |
| Finland | 7285        | 0.215            |
| France  | 8247        | 0.114            |
| Germany | 6123        | 0.132            |
| Greece  | 216         | 0.065            |
| Italy   | 4189        | 0.083            |
| Netherlands | 5484 | 0.154 |
| Norway  | 1097        | 0.174            |
| Portugal | 381        | 0.169            |
| Spain   | 4863        | 0.094            |
| Sweden  | 686         | 0.205            |
| Switzerland | 2061 | 0.109 |

\textsuperscript{a}Data obtained from ref\textsuperscript{23}.

### Table 3. HLA allele frequencies per country in Continental Western Europe.\textsuperscript{a}

| Country | Sample size (2n) | DRB1*01:01 Frequency | DRB1*13:02 frequency | DRB1*15:01 frequency |
|---------|------------------|----------------------|----------------------|----------------------|
| Austria | 400              | 0.102                | 0.062                | 0.115                |
| Belgium | 198              | 0.086                | 0.035                | 0.123 (2n=408)\textsuperscript{b} |
| Denmark | 110              | 0.130                | 0.056                | 0.176                |
| Finland | 482              | 0.107                | 0.025                | 0.104                |
| France  | 1260             | 0.082                | 0.047                | 0.109                |
| Germany | 140300           | 0.092                | 0.043                | 0.144                |
| Greece  | 1848             | 0.060                | 0.033                | 0.045                |
| Italy   | 12562            | 0.060                | 0.038                | 0.055                |
| Netherlands | 3632 | 0.088 | 0.062 | 0.131 |
| Norway  | 362              | 0.080                | 0.050                | 0.170                |
| Portugal | 550              | 0.047                | 0.036                | 0.069                |
| Spain   | 3850             | 0.057                | 0.033                | 0.140                |
| Sweden  | 568              | 0.085                | 0.038                | 0.111                |
| Switzerland | 41664 | 0.078 | 0.053 | 0.109 |

\textsuperscript{a} Obtained from allelefrequencies.net October 19, 2019. \textsuperscript{b} Data from ref\textsuperscript{24}.

**Statistical analyses.** Regression and correlation analyses were used to evaluate the association between the population frequency of each of the three HLA alleles, DRB1*01:01, DRB1*13:02, and DRB1*15:01 (alone and combined), and the prevalence of dementia in Continental Western Europe. All statistical analyses were conducted using the IBM-SPSS statistical package (version 23).

### Results

**Unique HLA allele effects on dementia prevalence**

For each of the three alleles, the prevalence of dementia decreased exponentially with increasing allele frequency (Figures 1-3). In each case, the effects were highly statistically significant (DRB1*01:01: $P = 0.003$; DRB1*13:02: $P = 0.008$; DRB1*15:01: $P = 0.007$) and accounted for at least 46.8% of the variance in dementia prevalence (DRB1*01:01: $R^2 = 0.530$, Fig. 1; DRB1*13:02, $R^2 = 0.468$, Figure 2; DRB1*15:01: $R^2 = 0.471$, Figure 3). These effects were independent of apoE4 prevalence (partial correlation, with apoE4 prevalence partialed...
out: DRB1*01:01, r = -0.695, P = 0.008; DRB1*13:02, r = -0.782, P = 0.002; DRB1*15:01, r = -0.692, P = 0.016). Figure 4 illustrates differences in the magnitude of allele frequency effect on dementia prevalence as evidenced by the different slopes; of these, DRB1*13:02 had the steepest slope indicating that the protective effects for DRB1*13:02 are stronger than those for DRB1*01:01 and DRB1*15:01.

Combined HLA effects on dementia prevalence

The frequencies of the three HLA alleles were uncorrelated (Spearman’s rho ranged from 0.38 to 0.46; P’s > 0.095); therefore, we summed the individual allele frequencies as an estimate of the population frequency for the presence of any of the three alleles (DRB1*01:01 or DRB1*13:02 or DRB1*15:01) and evaluated the effects of this sum on dementia prevalence:

$$ f_{[3 \text{ alleles}]} = f_{01:01} + f_{13:02} + f_{15:01} \quad (1) $$

Dementia Prevalence (%) = $2.92e^{-2.03f_{[3 \text{ alleles}]}} \quad (2)$

This model (Figure 5) was highly statistically significant (P = 0.003) and explained 67.3% of the variance ($R^2 = 0.673$). By taking the natural logarithms (ln) on both sides, we get, equivalently,

$$ \ln(\text{Dementia Prevalence %}) = \ln(2.92) - 2.03f_{[3 \text{ alleles}]} \quad (3) $$

This effect was robust (Spearman’s rank correlation= -0.807, P = 0.0005), even when the apoE4 frequency was partialled out (partial r = -0.806, P = 0.0008).

We also evaluated the effects of the three alleles on dementia prevalence in those aged 65 and older. Similar to the above findings, the population frequency of the three alleles was significantly associated with dementia prevalence (Figure 6; $P = 0.004$, $R^2 = 0.479$) and was highly protective:

Dementia Prevalence in >65 y (%) = $13.48e^{-2.24f_{[3 \text{ alleles}]}} \quad (4)$
Finally, we evaluated the effects of the population frequency of these three alleles on the change in dementia prevalence between 1990 and 2016. Results of this analysis indicated that the sum of the population frequency of these three HLA alleles was significantly associated with a decrease in dementia prevalence observed over the last 26 years ($P = 0.006, R^2 = 0.482$). That is, countries for which the frequency of these three alleles is higher saw a greater reduction in dementia prevalence during that time (Figure 7).

Discussion

The results of the current study demonstrate robust protective effects of three common Class II (DRB1) HLA alleles on dementia prevalence in CWE. Since Class II HLA alleles play an essential role in antibody production and immunological memory to facilitate host protection in the event of re-exposure to viruses and other foreign pathogens, the effects observed here implicate foreign pathogens in dementia prevalence. That is, in countries for which the frequency of these three alleles is higher saw a greater reduction in dementia prevalence during that time (Figure 7).

It is remarkable that 67% of the variance in dementia prevalence in CWE and 48% of the variance in the change in prevalence of dementia between 1990 and 2016 is accounted for by the three HLA alleles investigated here. It is likely that the remaining variance is attributable to other genetic influences and lifestyle factors such as diet and exercise. Indeed, modifiable risk factors are estimated to account for $\sim 35\%$ of dementia risk. Thus, at the population level, these three HLA alleles coupled with lifestyle factors account for nearly all of the variance in dementia risk. Although apoE4 has been widely associated with dementia, prior studies have demonstrated that the effects of protective HLA alleles are independent of apoE4.

In light of that, we have speculated that apoE4 effects are secondary to HLA. That is, we have proposed that given an HLA-antigen match (i.e., with sufficient binding affinity and immunogenicity) the risk associated with apoE4 status is minimized. However, in the absence of an HLA-antigen match, persistent antigens cause neural damage. Since one role of apoE is to facilitate neuronal repair, the damage caused by persistent antigens may stimulate neuronal repair. For apoE2 and apoE3 carriers, damaged neurons may be successfully repaired; however, given the neurotoxic effects of apoE4, additional neuronal damage may occur in apoE4 carriers. In this hypothesized model, the effects of apoE4 are downstream and HLA, instead, plays a crucial initial role.

Conclusions

The current findings bolster prior work demonstrating immunogenetic protection against dementia and highlight identification and elimination of foreign antigens as a potential avenue for dementia prevention.

Limitations

HLA is known to vary by region and ethnicity, presumably as a result of evolutionary adaptations related to population differences in pathogen exposure. Consequently, the highly protective effects of the three alleles studied here may not generalize worldwide. That is, it is likely that other protective HLA alleles will be identified in other regions or in populations not characterized primarily by European ancestry due to superior ability of those alleles in eliminating pathogens that are less common in CWE. Furthermore, the protective effects here are specific to dementia and do not preclude the possibility that these alleles are associated with risk for other conditions.

Acknowledgments

Funding: Partial funding for this study was provided by the University of Minnesota (the Kunin Professorship for Women’s Healthy Brain Aging, the Brain and Genomics Fund, the McKnight Presidential Chair of Cognitive Neuroscience, and the American Legion Brain Sciences
Chair). The sponsors had no role in the current study design, analysis or interpretation, or in the writing of this paper. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.

**Author contributions:** LMJ and APG contributed to data analysis and writing the manuscript.

**Competing interests:** The authors declare no competing interests.

**Data and materials availability:** All data are available in references provided and at allelefrequencies.net.

**References**

1. James LM, Christova P, Lewis SM, et al. Protective effect of human leukocyte antigen (HLA) allele DRB1*13:02 on age-related brain gray matter volume reduction in healthy women. EBioMedicine. 2018; 29: 31-37.

2. James LM, Dolan S, Leuthold AC, et al. The effects of human leukocyte antigen DRB1*13 and apolipoprotein E type 4 allele on age-related variability of synchronous neural interactions in healthy women. EBioMedicine. 2018; 35: 288-94.

3. James LM, Georgopoulos AP. The Human Leukocyte Antigen (HLA) DRB1*13:02 Allele Protects against Dementia in Continental Western Europe. J Neurol Neuromed. 2019; 4(5): 1-6.

4. James LM, Georgopoulos AP. Human leukocyte antigen as a key factor in preventing dementia and associated apolipoprotein E4 risk. [published online April 12, 2019]. Front Aging Neurosci. doi:10.3389/ fnagi.2019.00082.

5. James LM, Georgopoulos AP. Persistent antigens hypothesis The human leukocyte antigen (HLA) connection. J Neurol Neuromed. 2018; 3(6): 27-31. doi:10.29245/2572.942X/2018/6.1235

6. James LM, Georgopoulos AP. Dementias caused by persistent pathogens and the role of HLA protection against them. J Neurol Neuromed. 2020; 5(1): 1-11.

7. Mawanda F, Wallace R. Can infections cause Alzheimer’s disease? Epidemiol Rev. 2013; 35: 161-90. doi:10.1093/epirev/mxs007

8. Itzhaki RF. Corroboration of a major role for herpes simplex virus type 1 in Alzheimer’s disease. Front Aging Neurosci. 2018; 10: e00324. doi: 10.3389/fnagi.2018.00324.

9. Bergström TF, Josefsson A, Erlich HA, et al. Recent origin of HLA-DRB1 alleles and implications for human evolution. Nat Genet. 1998; 18: 237.

10. Buhler S, Sanchez-Mazas A. HLA DNA sequence variation among human populations: molecular signatures of demographic and selective events. PLoS One. 2011; 6(2): e14643. doi:10.1371/journal.pone.0014643.

11. Mack SJ, Cano P, Hollenbach JA, et al. Common and well-documented HLA alleles: 2012 update to the CWD catalogue. Tissue Antigens. 2013; 81(4): 194-203. doi:10.1111/tan.12093.

12. Maiers M, Gragert I, Klitz W. High resolution HLA alleles and haplotypes in the US population. Human Immunol. 2007; 68: 779-788. doi:10.1016/j.humimm.2007.04.005.

13. Bettencourt A, Carvalho C, Leal B, et al. The protective role of HLA-DRB1*13 in autoimmune diseases. J Immunol Res. 2015; 2015; e948723. doi:10.1155/2015/948723.

14. Furuikawa H, Oka S, Tsuchiya N, et al. The role of common protective alleles HLA-DRB1*13 among systemic autoimmune diseases. Genes Immun. 2017; 18(1): 1-7. doi:10.1038/gene.2016.40.

15. Georgopoulos AP, James LM, Mahan MY, et al. Reduced human leukocyte antigen (HLA) protection in Gulf War Illness GWI. EBioMedicine. 2016; 3: 79-85. doi:10.1016/j.ebiom.2015.11.037

16. James LM, Christova P, Engdahl BE, et al. Human leukocyte antigen (HLA) and Gulf War Illness (GWI): HLA-DRB1*13:02 spares subcortical atrophy in Gulf War veterans. EBioMedicine. 2017; 26: 126-131. doi: 10.1016/j.ebiom.2017.11.005.

17. Hill AV, Allsopp CE, Kwiatkowski D, et al. Common West African HLA antigens are associated with protection from severe malaria. Nature. 1991 Aug; 352(6366): 595.

18. Ranasinghe S, Cutler S, Davis I, et al. Association of HLA-DRB1-restricted CD4+ T cell responses with HIV immune control. Nature medicine. 2013 Jul; 19(7): 930.

19. Singh R, Kaul R, Kaul A, et al. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol. 2007; 13(12): 1770-87.

20. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993; 261(5123): 921-3.

21. Nichols E, Szeoeke CEI, Volkeet SE, et al. Global, regional, and national burden of Alzheimer’s disease and other dementias 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019; 18: 88-106. doi:10.1016/S1474-4422(18)30403-4.

22. Population Reference Bureau. 2016 world population data sheet with a special focus on human needs and sustainable resources. Population Reference Bureau, Washington, DC, 2016. https://www.prb.org/2016-world-population-data-sheet/. Accessed February 5, 2019.

23. Singh PP, Singh M, Mastana SS. APOE distribution in world populations with new data from India and the UK. Ann Hum Biol. 2006; 33(3): 279-308. doi:10.1080/03014460600594513.

24. Ghanbanasani MZ, Gu XX, Spasen M, et al. Importance of HLA-DRB1 and DQA1 genes and of the amino acid polymorphisms in the functional domain of DRβ1 chain in multiple sclerosis. J Neuroimmunol. 1995; 59: 77-82.

25. Livingston G, Sommerland A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2017; 390(10113): 2673-2734. doi:10.1016/S0140-6736(17)31363-6.

26. Mahley RW, Huang Y. Apolipoprotein E sets the stage: Response to injury triggers neuropathology. Neuron. 2012; 76: 871-885. doi:10.1016/j.neuron.2012.11.020.